Report copyright - COLORECTAL CANCER: STATE OF THE ART - … · bevacizumab or FOLFOXIRI plus bevacizumab [II, A]. Patients must be re-evaluated regularly in order to prevent the overtreatment of resectable
Please pass captcha verification before submit form